| |
 |
|
|
Science Forum Index » Medicine - Cancer Forum » Recent review articles about colorectal cancer...
Page 1 of 1
|
| Author |
Message |
| ... |
 Posted: Sat Aug 02, 2008 8:10 am |
|
|
|
Guest
|
Recent review articles about colorectal cancer:
Targeted therapy of cancer: new roles for pathologists in colorectal
cancer.
Hamilton SR.
Mod Pathol. 2008 May;21 Suppl 2:S23-30.
Combination regimen with statins and NSAIDs: a promising strategy for
cancer chemoprevention.
Xiao H, Yang CS.
Int J Cancer. 2008 Sep 1;123(5):983-90.
Human colon cancer stem cells: a new paradigm in gastrointestinal
oncology.
Boman BM, Huang E.
J Clin Oncol. 2008 Jun 10;26(17):2828-38.
C-reactive protein and colorectal cancer risk: a systematic review of
prospective studies.
Tsilidis KK, Branchini C, Guallar E, Helzlsouer KJ, Erlinger TP, Platz
EA.
Int J Cancer. 2008 Sep 1;123(5):1133-40.
Endpoints and surrogate endpoints in colorectal cancer: a review of
recent developments.
Piedbois P, Buyse M.
Curr Opin Oncol. 2008 Jul;20(4):466-71.
First-line chemotherapy in metastatic colorectal cancer: new
approaches and therapeutic algorithms. Always hit hard first?
Loupakis F, Masi G, Vasile E, Falcone A.
Curr Opin Oncol. 2008 Jul;20(4):459-65.
Why hormones protect against large bowel cancer: old ideas, new
evidence.
Newcomb PA, Pocobelli G, Chia V.
Adv Exp Med Biol. 2008;617:259-69.
Poor usage of HUGO standard gene nomenclature in cancer marker
studies.
Lacroix M.
Int J Biol Markers. 2008 April - June;23(2):123-126.
Hyperinduction of Wnt activity: a new paradigm for the treatment of
colorectal cancer?
Bordonaro M, Lazarova DL, Sartorelli AC.
Oncol Res. 2008;17(1):1-9.
Colonic crypt organization and tumorigenesis.
Humphries A, Wright NA.
Nat Rev Cancer. 2008 Jun;8(6):415-24.
Cochrane systematic review of colorectal cancer screening using the
fecal occult blood test (hemoccult): an update.
Hewitson P, Glasziou P, Watson E, Towler B, Irwig L.
Am J Gastroenterol. 2008 Jun;103(6):1541-9.
Foxp3 and microsatellite stability phenotype in colorectal cancer.
Loddenkemper C, Nagorsen D, Zeitz M.
Gut. 2008 Jun;57(6):725-6.
Signaling molecules: the pathogenic role of the IL-6/STAT-3 trans
signaling pathway in intestinal inflammation and in colonic cancer.
Atreya R, Neurath MF.
Curr Drug Targets. 2008 May;9(5):369-74.
Targeting metastatic colorectal cancer in 2008: a long way from 5-FU.
Pohl A, Zhang W, Ning Y, Manegold PC, Lurje G, Lenz HJ.
Oncology (Williston Park). 2008 Apr 15;22(4):456-62
Systemic treatment of colorectal cancer.
Wolpin BM, Mayer RJ.
Gastroenterology. 2008 May;134(5):1296-310.
Bevacizumab and oxaliplatin-based chemotherapy in metastatic
colorectal cancer.
Beatty GL, Giantonio BJ.
Expert Rev Anticancer Ther. 2008 May;8(5):683-8.
Cancer screening in the United States, 2008: a review of current
American Cancer Society guidelines and cancer screening issues.
Smith RA, Cokkinides V, Brawley OW.
CA Cancer J Clin. 2008 May-Jun;58(3):161-79.
Butyrate and Wnt signaling: a possible solution to the puzzle of
dietary fiber and colon cancer risk?
Bordonaro M, Lazarova DL, Sartorelli AC.
Cell Cycle. 2008 May;7(9):1178-83.
Compound heterozygosity for two MSH6 mutations in a patient with early
onset colorectal cancer, vitiligo and systemic lupus
erythematosus.Capecitabine plus oxaliplatin for the treatment of
colorectal cancer.
Rahner N, Höefler G, Högenauer C, Lackner C, Steinke V, Sengteller M,
Friedl W, Aretz S, Propping P, Mangold E, Walldorf C.
Am J Med Genet A. 2008 May 15;146A(10):1314-9.
(contact at InTextoResearch: Marc Lacroix, Baelen, Wallonia, Belgium -
scimedweb at (no spam) mail.com) |
|
|
| Back to top |
|
| |
|
Page 1 of 1
All times are GMT - 5 Hours
The time now is Thu Dec 04, 2008 4:16 pm
|
|